Mr. Y. Mark Xu is the Co-founder, Chairman, CEO and President of Xynomic Pharmaceuticals, Inc. Mr. Xu is a successful Silicon Valley-China serial entrepreneur. During 2005-2009 Mr. Xu co-founded Bridge Labs and Pacific Biopharma Group, which merged with Pharmacyclics in 2009. Mr. Xu, through these 2 ventures, generated ~RMB 2.5 billion for co-founders and investors. During 2009-2016 Mr. Xu served as the Greater China General Manager of Trout Group, the largest investment bank and advisory firm in the US focusing exclusively on serving small-to-mid sized life sciences companies. Before 2005 Mr. Xu held progressive positions in the US at leading MNCs including Schering, McKesson (world’s largest pharmaceutical distribution company), Stanford Research Institute International, BAS, and UL. Mr. Xu holds a MBA from Stanford University, a MS in Chemistry from Purdue University and a BA in Chemistry (Magna Cum Laude) from Hanover College.
Jason Wu, PhD
Chief Operating Officer
Dr. Wu has over 20 years of working experience in pharmaceutical industry in US and China. He held senior management positions in a number of pharmaceutical companies and research institutes, including Lilly, Merck, Hutchison Medi Pharma, and Institute of Materia Medica. He has a PhD from Purdue University. Dr. Wu is an adjunct professor at the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Science (CAMS). Dr. Wu has been working as a consultant for Chinese and western life sciences companies since 2012, advising clients on technology transfer, licensing, and M&A activities.
Dr. Bing Zhao, MD
Vice President of Clinical & Regulatory Affairs, Greater China
Dr. Zhao received his BS, MS, and MD (all majored in Oncology) from Xi’an Jiaotong University Health Science Center. He was a practicing oncologist in Xi’An, China from 1997-2007. In 2008 joined BMS in its clinical affairs department and since then has assumed increasing responsibilities as a clinical trial expert at Beijing H&J CRO International (Vice President and Director of Clinical Center), Shanghai Rundo CRO (Director of Clinical Center) ,3D-HTS (Vice President),Osmunda (Executive Vice General Manager and Director of Clinical Center)
Dr. Sophia Paspal
Chief Development Officer
Dr. Paspal assumes overall responsibility to strengthen Xynomic’s regulatory compliance and quality assurance functions. Dr. Paspal brings 20 years of relevant global industry experience. From 2017 to January 2019, Dr. Paspal worked at Capricor Therapeutics, Inc. and Cellics Therapeutics, Inc., holding the same title. From 2015 to 2017 Dr. Paspal worked as the Director of Regulatory Affairs, Oncology, at Halozyme Therapeutics Inc. From 2014 to 2015 Dr. Paspal worked as Associate Director of Regulatory Affairs, Neurology, for Dart NeuroScience LLC. Prior to 2014, Dr. Paspal worked for companies such as Shire PLC, Allergan, Inc., and Pfizer in developing and implementing regulatory strategies and obtaining and maintaining regulatory approvals. Dr. Paspal holds Regulatory Affairs Certification (RAC) and Drug Development Certification from Temple University RA and QA Program. Dr. Paspal holds a Bachelor of Science in Chemistry and Ph.D. in Pharmaceutics from the University of Minnesota, Twin Cities in Minnesota.